ShebliAtrashMDMS, FACP

Clinical Trials

• Therapeutic Research in Multiple Myeloma Start of enrollment: 2003 Aug 01

  Completed

• UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Start of enrollment: 2008 Jul 01

  Active, not recruiting

  Phase 3

• Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy Start of enrollment: 2009 Mar 01

  Active, not recruiting

  Phase 2

• UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Start of enrollment: 2010 Apr 01

  Completed

  Phase 3

• UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma Start of enrollment: 2013 Apr 01

  Completed

  Phase 2

• UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Start of enrollment: 2015 Mar 01

  Withdrawn

  Phase 2

• S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Start of enrollment: 2019 Aug 13

  Recruiting

  Phase 3

• Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma Start of enrollment: 2021 May 19

  Active, not recruiting

  Phase 1, Phase 2

• Join now to see all